The use of G-CSF following antileukemic therapy has been shown to reduce leukopenia by a median of 4 days after S-HAM induction as well as after other regimens such as high-dose AraC consolidation therapy [15, 16]. The gene discussed is CSF3; the disease is Decreased total leukocyte count.